

CURRICULUM VITAE

Jeanette Marie Tetrault, MD, FACP, FASAM

Version Date: 5/11/2026

Contact Information:

Address 367 Cedar Street
Ste Suite 305
New Haven, CT 06510
Phone: 1 (203) 785-5208
Email: jeanette.tetrault@yale.edu

School: Yale School of Medicine

Education:

09/1993 - 05/1997 BA, Boston University, Biology, Boston, MA
07/1997 - 05/2001 MD, Boston University School of Medicine, Boston, MA

Career/Academic Appointments:

01/2001 - 01/2004 Medical Intern and Resident, Internal Medicine-Primary Care, Yale School of
Medicine, New Haven, CT
01/2002 Internship, Yale School of Medicine
01/2004 - 01/2005 Chief Resident, Internal Medicine-Primary Care, Yale School of Medicine, New
Haven, CT
07/2004 - 06/2005 Instructor, Internal Medicine, Yale School of Medicine, New Haven, CT
01/2005 - 01/2007 Ambulatory Care Fellow, Clinical Epidemiology Research Fellow, West Haven VA
Hospital, West Haven, CT
07/2005 - 06/2007 Postdoctoral Fellow, General Medicine, Yale School of Medicine, New Haven, CT
07/2007 - 06/2008 Instructor, General Medicine, Yale School of Medicine, New Haven, CT
07/2008 - 06/2015 Assistant Professor, General Medicine, Yale School of Medicine, New Haven, CT
07/2015 - 06/2021 Associate Professor on Term, General Medicine, Yale School of Medicine, New
Haven, CT
07/2020 - Present Professor, General Medicine, Yale School of Medicine, New Haven, CT
03/2021 - 06/2030 Professor, Chronic Disease Epidemiology, Yale School of Medicine, New Haven, CT

Administrative Positions:

2014 - Present Program Director, Addiction Medicine Fellowship, Internal Medicine, Yale School
of Medicine, New Haven, CT

2014 - 2020	Co-Director, Addiction Recovery Clinic: Chronic Disease Management/Residency Education Clinic, St. Raphael's Campus, Internal Medicine, Yale New Haven Hosp, New Haven, CT
2019 - Present	Associate Director for Education and Training, Program in Addiction Medicine, Internal Medicine, Yale School of Medicine, New Haven, CT
2019 - Present	Academic Advisor, Office of Student Affairs, Yale School of Medicine, New Haven, CT
2021 - Present	Professor, Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT
2021 - Present	Vice-chief for Education, General Internal Medicine, Yale School of Medicine, New Haven, CT
2023 - Present	Head of Advisory House, Hamburg House, Office of Student Affairs, Yale School of Medicine, New Haven, CT

Board Certification:

2004 - 2015	AB of Internal Medicine, Internal Medicine
2015 - 2026	AB of Internal Medicine, Internal Medicine, recertification
2018 - 2029	AB of Preventive Medicine, Addiction Medicine

Professional Honors & Recognition:

International/National/Regional

1997	Phi Beta Kapa, Boston University
2001	Job E. Fuchs Scholarship Award for Humanism in Medicine, Boston University School of Medicine
2006	Best Research Abstract in Women's Medicine, Society of General Internal Medicine Annual Meeting, Los Angeles, CA
2010	Selected as a Hamolsky Award Finalist for Outstanding Junior Investigator Oral Abstract Presentation, 33rd Annual Society of General Internal Medicine Meeting, Minneapolis, MN
2010	Certified as an HIV Specialist, American Academy of HIV Medicine
2010	Selected as Invited Fellow, American College of Physicians
2011	Selected as Co-chair Alcohol, Tobacco, and Other Drug Use Interest Group, Society of General Internal Medicine
2011	Loan Repayment Award Recipient, National Institute of Health
2013	Clinician Educator of the Year, Society of General Internal Medicine-New England Regional Award for Excellence
2014	Elected President, Society of General Internal Medicine, New England Region
2017	Recognized Macy Foundation Faculty Scholar, Macy Foundation
2017	Elected as Milestones Committee Chair, The Addiction Medicine Foundation
2018	Awarded W. Anderson Spickard Excellence in Mentorship Award, Association for Multidisciplinary Education and Research in Substance Use and Addiction
2019	Elected as President , American College of Academic Addiction Medicine
2021	Annual Training Directors Award, American Society of Addiction Medicine

2023 John P. McGovern Award for Excellence in Medical Education, Association for Multidisciplinary Education and Research in Substance Use and Addiction

Yale University/Yale School of Medicine/Hospital System

2004 Selected as Chief Medical Resident, Yale University Primary Care Internal Medicine Residency Program

2011 George Thornton Community Teacher of the Year Award, Yale School of Medicine Primary Care Internal Medicine Residency Program

Grants/Clinical Trials History:

Current Grants

Agency: Health Resources Services Administration
I.D.#: 6 T62HP49327-01-01
Title: Integrated Substance Use Disorder (SUD) Training Program
P.I.: Kenneth Morford
Role: Associate Director
Percent effort: 10%
Total costs: \$2,567,104.00 (of which \$38,143.00 indirects)
Project period: 07/01/2023 - 06/30/2028

Agency: Substance Abuse and Mental Health Services Administration
I.D.#: H79TI087364
Title: Responsive Integrated Substance Use Education: Project RISE
P.I.: Cara Borelli
Role: Co-Investigator
Percent effort: 10%
Total costs: \$553,756.00 (of which \$20,353.00 indirects)
Project period: 09/30/2024 - 09/29/2026

Agency: Substance Abuse and Mental Health Services Administration (SAMHSA)
I.D.#: H79SM090070
Title: Recognizing and Eliminating disparities in Addiction through Culturally informed Healthcare 2.0 (REACH 2.0)
P.I.: Reisner, Carly
Role: Associate Medical Director
Percent effort: 10%
Total costs: \$1,924,578.00 (of which \$112,990.00 indirects)
Project period: 09/30/2024 - 09/29/2029

Current Clinical Trials

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 1110009133

Title: PK/PD Comparison of Guanfacine ER and IR
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 12/15/2011 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 1308012557
Title: Does Guanfacine Attenuate Stress-Induced Drinking?
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/19/2013 - ongoing

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 1509016500
Title: Working with HIV clinics to adopt addiction treatments using implementation facilitation (WHAT IF?)
P.I.: David Fiellin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 12/02/2015 - ongoing

Agencies: Yale University
I.D.#: 2000021606
Title: Using the Lumme system to improve real-time alcohol detection
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/25/2017 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000021685
Title: Behavioral and Neurochemical Mechanisms Underlying Stress-Precipitated Drinking
P.I.: Terril Luce
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/04/2017 - ongoing

Agencies: Yale University
I.D.#: 2000021703
Title: Mavoglurant in Alcohol Drinking
P.I.: Suchitra Krishnan-Sarin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/20/2017 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000023970
Title: Mechanistic Evaluation of Guanfacine on Drinking Behavior
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/16/2018 - ongoing

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 2000026630
Title: Combining Varenicline and Guanfacine for Smoking Cessation
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/11/2020 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000028772
Title: The Effect of Acute Stress and Inflammation on Drinking
P.I.: Terril Luce
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/28/2020 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000029675
Title: Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
P.I.: Suchitra Krishnan-Sarin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Project period: 04/05/2021 - ongoing

Past Grants

Agency: SAMHSA
I.D.#: 1U79TI025362-01
Title: Yale-SBIRT Medical Health Professional Training Program
P.I.: Gail D'Onofrio
Role: Co-Investigator
Percent effort: 10%
Total costs: \$943,785.00
Project period: 09/01/2014 - 08/31/2017

Agency: NIDA
I.D.#: 1R01DA035616-01
Title: Using the VACS Index to track health outcomes associated with changes in drug use
P.I.: Fiellin, David and Amy Justice
Role: Co-Investigator
Percent effort: 7%
Total costs: \$1,190,178.00
Project period: 04/01/2013 - 02/29/2016

Agency: NHLBI
I.D.#: 1R18HL108788-01A1
Title: Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
Role: Co-Investigator
Percent effort: 7%
Total costs: \$731,166.00
Project period: 08/06/2012 - 07/31/2015

Agency: HRSA
I.D.#: D5FHP20670
Title: Training in Primary Care Medicine and Dentistry: Residency Training in Primary Care
P.I.: Nawaz, Haq
Role: Consultant
Percent effort: N/A
Total costs: \$111,338.00
Project period: 11/01/2010 - 08/31/2015

Agency: NIDA
I.D.#: 5R01DA020576
Title: Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence

P.I.: David Fiellin
Role: Co-Investigator
Percent effort: 5%
Total costs: \$2,865,450.00
Project period: 07/05/2007 - 04/30/2013

Agency: SAMHSA
I.D.#: 1U79TI020253-01
Title: The SBIRT Training in Yale Residency Programs: Implementation and Dissemination to implement and disseminate SBIRT curriculum for alcohol/drugs into targeted Yale residencies and beyond

P.I.: Gail D'Onofrio
Role: Co-Investigator
Percent effort: 15%
Total costs: \$1,869,686.00
Project period: 09/30/2008 - 09/13/2013

Agency: HRSA
I.D.#: D5HHP18960
Title: Training in Primary Care Medicine and Dentistry: Residency Training in Primary Care

P.I.: Nawaz, Haq
Role: Consultant
Percent effort: N/A
Total costs: \$88,663.00
Project period: 07/01/2010 - 06/30/2013

Agency: HRSA
I.D.#: 1H4AHA22762-01-00
Title: Capacity Building for the Yale Graduate Medical Education HIV Training Program

P.I.: Barakat, Lydia
Role: Co-Investigator
Percent effort: 5%
Total costs: \$450,000.00
Project period: 09/01/2011 - 09/30/2014

Agency: HRSA
I.D.#: 3H80CS00741
Title: Substance Abuse Service Expansion for Federally Qualified Health Centers
P.I.: Lagarde, Suzanne
Role: Co-Investigator
Percent effort: 20%
Total costs: \$48,265.00

Project period: 04/01/2016 - 03/31/2017

Agency: HRSA
I.D.#: D33HP26994
Title: Preventive Medicine Residencies
P.I.: Nawaz, Haq
Role: Consultant
Percent effort: N/A
Total costs: \$500,000.00
Project period: 07/01/2014 - 06/30/2018

Agency: HRSA
I.D.#: T0BHP28572
Title: Primary Care Training and Enhancement
P.I.: Nawaz, Haq
Role: Consultant
Percent effort: N/A
Total costs: \$349,998.00
Project period: 07/01/2015 - 06/30/2020

Agency: HRSA
I.D.#: T0BHP3107
Title: Primary Care Training and Enhancement
Role: Principal Investigator
Percent effort: 20%
Total costs: \$1,976,565.00
Project period: 07/01/2019 - 06/30/2024

Agency: SAMHSA
I.D.#: H79TI081358
Title: Minority Fellowship Program
P.I.: Cathryn Cates-Wessel
Role: Co-Investigator
Percent effort: 5%
Total costs: \$4,998,265.00
Project period: 09/30/2018 - 09/29/2023

Agency: SAMHSA
I.D.#: H79TI081659
Title: Yale MAT Training Program
P.I.: Gail D'Onofrio
Role: Co-Investigator
Percent effort: 5%
Total costs: \$449,727.00

Project period: 09/30/2018 - 09/29/2021

Agency: Macy Foundation
I.D.#: AWD0000485
Title: Macy Faculty Scholar Award
Role: Principal Investigator
Percent effort: 50%
Total costs: \$278,993.00
Project period: 09/01/2017 - 08/31/2019

Agency: HRSA
I.D.#: 1 T25HP37631
Title: Yale Addiction Fellowship Expansion Program
Role: Principal Investigator
Percent effort: 10%
Total costs: \$2,660,078.00
Project period: 06/03/2020 - 06/30/2025

Agency: Substance Abuse and Mental Health Services Administration
I.D.#: 1 H79 FG0000-23
Title: Expansion of Interprofessional Practitioner Substance Use Disorder Education
P.I.: Cates-Wessel, K
Role: Collaborator
Percent effort: N/A
Total costs: \$201,299.00
Project period: 09/30/2019 - 09/29/2021

Agency: US Department of State
I.D.#: SJO10021GR3024
Title: Yale – The University of Jordan Joint Training Program in Addiction Medicine
P.I.: Jeanette M. Tetrault
Role: Principle Investigator
Percent effort: 5%
Total costs: \$158,466.00
Project period: 07/15/2021 - 06/14/2023

Agency: Shatterproof
I.D.#: AWD0008883
Title: Shatterproof Reducing Healthcare Providers' Addiction Stigma to Better Serve Socially Vulnerable Communities
P.I.: Tetrault
Role: Co-Investigator; Site Principal Investigator
Percent effort: 10%
Total costs: \$200,000.00

Project period: 10/01/2022 - 09/30/2025

Agency: National Institute on Drug Abuse
I.D.#: 5UG1DAO15831-20
Title: National Institute on Drug Abuse Clinical Trial Network: New England Consortium Node: CTN0131; 0080; 0099; 0100; 0116,125, 0126
P.I.: Gail D'Onofrio
Role: Co-Investigator
Percent effort: 10%
Total costs: \$10,864,655.00
Project period: 03/01/2023 - 02/28/2024

Past Clinical Trials

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 0608001776
Title: Pain and Opioid Dependence (POD)
P.I.: Richard Schottenfeld
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/11/2006 - 09/20/2016

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 0702002391
Title: Do Pharmacological Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking?
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/06/2007 - 03/29/2018

Agencies: Pfizer Inc., U.S. Pharmaceuticals Group
I.D.#: 0907005525
Title: Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants with Alcohol Use Disorders
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/21/2009 - 06/27/2018

Agencies: Yale University

I.D.#: 1011007710
Title: Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
P.I.: Suchitra Krishnan-Sarin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/18/2011 - 03/21/2024

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 1111009293
Title: Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 01/20/2012 - 10/26/2017

Agencies: National Heart, Lung, and Blood Institute (NHLBI)
I.D.#: 1205010297
Title: Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/13/2012 - 07/02/2019

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 1310012843
Title: Achieving Cannabis Cessation - Evaluating N-Acetylcysteine Treatment (ACCENT)
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 12/16/2013 - 10/21/2015

Agencies: Yale University School of Medicine
I.D.#: 1410014714EXEMPT
Title: PrEP Implementation Among General Internists
P.I.: E. Jennifer Edelman
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/07/2014

Agencies: National Heart, Lung, and Blood Institute (NHLBI)
I.D.#: 1509016496
Title: Stress, Sleep and Arterial Stiffness
P.I.: Matthew Burg
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 11/19/2015 - 07/17/2023

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 1602017291
Title: Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/26/2016 - 03/29/2019

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000024941
Title: Imaging the effect of alcohol use on the Mu Opioid Receptor
P.I.: Suchitra Krishnan-Sarin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/15/2019 - 08/28/2023

Pending Clinical Trials

Agencies: University of Southern California
I.D.#: 2000042218
Title: A Multi-Site Trial of Tirzepatide for Smoking Cessation
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -

Agencies: Yale University
I.D.#: 2000027432
Title: Analysis of Patients Seen by Yale Addiction Medicine Consult Service
P.I.: Melissa Weimer
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 03/10/2020 - ongoing

Agencies: Yale University
I.D.#: 2000028376
Title: COVID Survey Study of YAMCS Patients
P.I.: Melissa Weimer
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/10/2020 - ongoing

Agencies: Alkermes, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000032770
Title: Using wearable devices to predict alcohol use events in heavy drinkers
P.I.: Walter Roberts
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/31/2022 - ongoing

Agencies: National Center for Advancing Translational Sciences (NCATS), Yale Center for Clinical Investigation
I.D.#: 2000034902
Title: Assessment and Development of Standard Practices for Initiation of Opioid Agonist Treatment (OAT) by Hospital based Addiction Consult Services
P.I.: Shawn Cohen
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/03/2023 - ongoing

Agencies: National Institute on Drug Abuse (NIDA)
I.D.#: 2000033271
Title: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment - A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial
P.I.: David Fiellin
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/05/2023 - ongoing

Agencies: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
I.D.#: 2000037439
Title: Apremilast for alcohol use disorder treatment in women and men

P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 04/03/2024 - ongoing

Agencies: -
I.D.#: 2000040391
Title: Phase 2 study of apremilast in women and men with alcohol use disorder
P.I.: Sherry McKee
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/25/2025 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. "Medical co-morbidities of substance abuse, Clinical Management, Special Populations". American Psychiatric Association; Faculty Instructor: Buprenorphine for the treatment of opioid dependence physician training course, Medical co-morbidities of substance abuse, Clinical Management, Special Populations, Orlando, FL, July 2007. (Oral Presentation)
2. "Medical co-morbidities of substance abuse, Clinical Management, Special Populations". American Psychiatric Association, Buprenorphine for the treatment of opioid dependence physician training course, Medical co-morbidities of substance abuse, Clinical Management, Special Populations, Orlando, FL, July 2007. (Oral Presentation)
3. "Buprenorphine and Medical Co-Morbidities". American Psychiatric Association and The Physicians Clinical Support System-Buprenorphine, Webinar, Buprenorphine and Medical Co-Morbidities, Washington, DC, July 2010. (Other)
4. "Marijuana: What every physician needs to know". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: What every physician needs to know, Harwich, MA, April 2012. (Other)
5. "For every ill there may be a pill: Treating substance use disorders with medication". American Society of Addiction Medicine, Fundamentals of Addiction Medicine, For every ill there may be a pill: Treating substance use disorders with medication, Orlando, FL, April 2013. (Oral Presentation)
6. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, April 2013. (Other)
7. "Substance Use and Abuse Multiple Small Feedings of the Mind". American College of Physicians Annual Meeting, Substance Use and Abuse Multiple Small Feedings of the Mind, Boston, MA, April 2014. (Other)
8. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, January 2015. (Other)

9. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, Boston, MA, February 2015. (Oral Presentation)
10. "Marijuana clinical and policy issues". Physicians Clinical Support System for Opioid Therapies, Small Group Discussion Webinar, Marijuana clinical and policy issues, Providence, RI, March 2015. (Other)
11. "Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder". Physicians Clinical Support System for Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder Webinar., Medication Assisted Treatment of Hepatitis C, HIV and Opioid Use Disorder, Providence, RI, March 2015. (Other)
12. "Involvement of nursing and other professions in alcohol screening and brief intervention: A critical review". International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA) Annual Conference; Precourse plenary presentation, Involvement of nursing and other professions in alcohol screening and brief intervention: A critical review, Atlanta, GA, September 2015. (Other)
13. "Adverse effects of marijuana use in adults". A public forum on The Marijuana Regulation, Control, and Taxation Act, Adverse effects of marijuana use in adults, Providence, RI, November 2015. (Oral Presentation)
14. "Training in Addiction Medicine: Possibilities in Vietnam". Hanoi Medical University, Visiting Professor, Training in Addiction Medicine: Possibilities in Vietnam, Hanoi, Hanoi, February 2016. (Oral Presentation)
15. "Training in Addiction Medicine: The U.S. Experience". Hanoi Medical University, Visiting Professor, Training in Addiction Medicine: The U.S. Experience, Hanoi, Hanoi, February 2016. (Oral Presentation)
16. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, Boston, MA, March 2016. (Oral Presentation)
17. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Harwich, MA, April 2016. (Oral Presentation)
18. "Office management of Opioid Use Disorder". Fundamentals of Addiction Medicine, Recognition Program, Tele ECHO clinics webinar., Office management of Opioid Use Disorder, Rockville, MD, August 2016. (Other)
19. "Cannabinoids". Fundamentals of Addiction Medicine, Recognition Program, Tele ECHO clinics webinar., Cannabinoids, Rockville, MD, October 2016. (Other)
20. "Building the Pipeline for Addiction Medicine Fellowship Applicants". Addiction Medicine Fellowship Directors Association Annual Meeting. Panel discussion moderator, Building the Pipeline for Addiction Medicine Fellowship Applicants, New Orleans, LA, April 2017. (Other)
21. "Screening and Treatment for Hepatitis C among People Who Use Drugs". American Society of Addiction Medicine Annual Meeting. Workshop facilitator, Screening and Treatment for Hepatitis C among People Who Use Drugs., New Orleans, LA, April 2017. (Other)
22. "Opening Pandora's Box: Introduction to Screening, Brief Intervention and Referral to Treatment". American Society of Addiction Medicine, Fundamentals of Addiction Medicine, Opening Pandora's Box: Introduction to Screening, Brief Intervention and Referral to Treatment, New Orleans, LA, April 2017. (Oral Presentation)

23. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Core faculty and lecturer, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Beverly, MA, April 2017. (Oral Presentation)
24. "Care in the Face of the Opioid Epidemic: How Teaching Hospitals are Reaching Underserved Communities". Association of American Medical Colleges, Congressional Briefing on the Opioid Crisis, one of three panelists, Care in the Face of the Opioid Epidemic: How Teaching Hospitals are Reaching Underserved Communities, Washington, DC, October 2017. (Other)
25. "Marijuana: Clearing the Smoke on Clinical and Policy Issues". Chief Resident Immersion Training in Addiction Medicine Course, Core faculty and lecturer, Marijuana: Clearing the Smoke on Clinical and Policy Issues, Beverly, MA, April 2018. (Oral Presentation)
26. "Opportunities and Barriers: Education and training to expand treatment". National Academy of Science Engineering and Medicine. Workshop for the Committee on Medication Assisted Treatment for Opioid Use Disorder, Opportunities and Barriers: Education and training to expand treatment.", Washington, DC, October 2018. (Other)
27. "Breaking Badness: The HIV Provider's Role in Caring for Patients with Substance Use". University of California San Francisco. HIV Medicine Grand Rounds, Breaking badness: The HIV provider's role in caring for patients with substance use, San Francisco, CA, November 2018. (Oral Presentation)
28. "Achieving HCV Elimination in the US: Next steps". Clinical Care Options. Panelist, "Achieving HCV Elimination in the US: Next steps.", Orlando, FL, January 2019. (Other)
29. "Keys to setting up a successful Addiction Medicine Fellowship Program". American Society of Addiction Medicine. Workshop facilitator, "Keys to setting up a successful Addiction Medicine Fellowship Program.", Orlando, FL, April 2019. (Oral Presentation)
30. "The Role of the Addiction Medicine Specialist in the ED". Building the Addiction Medicine Workforce: Giving Americans Access to the Care They Need. Office of National Drug Control and Policy, White House Conference, Panel speaker, "The Role of the Addiction Medicine Specialist in the ED", Washington, DC, June 2019. (Oral Presentation)
31. "Building the Addiction Medicine Workforce: All Hands on Deck". American Society of Addiction Medicine 51st Annual Meeting. Symposia panelist., Building the Addiction Medicine Workforce: All Hands on Deck, Online annual meeting, April 2020. (Lecture)
32. "Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.". Harvard Medical School-Beth Israel Deaconess Hospital, Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center., Grand Rounds Conference held virtually due to COVID19 pandemic, October 2020. (Lecture)
33. "Cannabis: Clearing the Smoke on Clinical and Policy Issues". Chief Resident, Fellow and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Cannabis: Clearing the Smoke on Clinical and Policy Issues, Four day intensive training program on teaching and research on Addiction Medicine. Conference held virtually due to COVID-19 pandemic., October 2020. (Oral Presentation)
34. "Introduction to Motivational Interviewing: Helping People Change". Chief Resident, Fellow, and Junior Faculty Immersion Training Conference, Boston University School of Medicine, Introduction to Motivational Interviewing: Helping People Change, Four day intensive training program on teaching and research on Addiction Medicine. Conference held virtually due to COVID-19 pandemic., October 2020. (Oral Presentation)

35. "Health Professional Education and Training Workgroup Panelist". National Academy of Medicine, Washington DC, Health Professional Education and Training Workgroup Panelist, Served as panelist addressing the The Action Collaborative on Countering the U.S. Opioid Epidemic. Conference held virtually due to COVID-19 pandemic., November 2020. (Other)
36. "Addiction Medicine Milestones and GME Stakeholders Confronting the Opioid Epidemic". Accreditation Council of Graduate Medical Education, Chicago IL, Addiction Medicine Milestones and GME Stakeholders Confronting the Opioid Epidemic, Served as session moderator and panelist. Conference held virtually due to COVID-19 pandemic., April 2021. (Other)
37. "Cannabis". Boston University, Chief Resident Immersion Training Conference, Beverly, MA, April 2022. (Lecture)
38. "Motivational Interviewing". Boston University, Chief Resident Immersion Training Conference, Beverly, MA, April 2022. (Lecture)
39. "Co-Occurring Medical Disorders among Individuals who Inject Drugs". American College of Academic Addiction Medicine (ACAAM), ACAAM National Didactic Series, Virtual presentation to all ACAAM Addiction Medicine Fellowships, November 2022. (Lecture)
40. "Featured Plenary: Preparing Learners to Care for Substance Use Disorder". Accreditation Council of Graduate Medical Education (ACGME), Accreditation Council of Graduate Medical Education (ACGME) Annual Conference, Nashville, TN, February 2023. (Address)
41. "Taking a Substance Use History". University of Jordan, Yale University of Jordan Joint Training Program in Addiction Medicine, Amman, Amman Governorate, May 2023. (Demonstration)
42. "Yale University of Jordan Joint Training Program in Addiction Medicine". University of Jordan, Yale University of Jordan Joint Training Program in Addiction Medicine, Amman, Amman Governorate, May 2023. (Lecture)
43. "Advocacy, equity, and evidence: Centering the needs of patients and learners". AMERSA, Association for Multidisciplinary Education and Research on Substance use and Addiction (AMERSA) , Washington, DC, November 2023. (Address)
44. "Commonly used substances and infectious complications in racial and ethnic minoritized populations". Reducing and Eliminating Addiction through Culturally Informed Healthcare, San Juan, San Juan, July 2024. (Lecture)
45. "Taking a Stigma Free Addiction History". Ohio State University, Ohio State University Internal Medicine Resident Noon Conference, Columbus, OH, April 2025. (Lecture)
46. "From Myths to Medications: Outpatient Management of Alcohol Use Disorder". Ohio State University, Ohio State University General Internal Medicine Faculty Development Workshop, Columbus, OH, May 2025. (Lecture)
47. "Do No Harm! But Do Harm Reduction: Centering the Needs of Patients and Learners". Ohio State University, Ohio State University Evelyn Pintz Grand Rounds, Columbus, OH, May 2025. (Lecture)
48. "Chronic Infectious Complications of Opioid Use Disorder". Ophelia Health, Ophelia Health Grand Rounds, Grand Rounds Lecture given to Ophelia Health Network, a nationwide telehealth substance use treatment provider, June 2025. (Lecture)
49. "Integrating Addiction Medicine into Health Professions Education to Prevent Alcohol-Related Cancers". 6th Annual International Conference on Alcohol and Cancer, Edipsos, Central Greece, May 2026. (Oral Presentation)

Regional

1. "Prescription Drug Abuse". Nurse Practitioner Association Annual Meeting, Prescription Drug Abuse, Verona, NY, October 2008. (Oral Presentation)
2. "Screening Brief Intervention and Referral to Treatment (SBIRT) Program". Medical Grand Rounds, Albany Medical Center, Screening Brief Intervention and Referral to Treatment (SBIRT) Program, Albany, NY, June 2010. (Oral Presentation)
3. "Screening, Brief Intervention and Referral to Treatment in the Emergency Department". Medical Grand Rounds, Albany Medical Center, Screening, Brief Intervention and Referral to Treatment in the Emergency Department, Albany, NY, June 2011. (Oral Presentation)
4. "Introduction to Screening, Brief Intervention, and Referral to Treatment". Albany Medical Center, Introduction to Screening, Brief Intervention, and Referral to Treatment., Albany, NY, June 2011. (Oral Presentation)
5. "Outpatient management of opioid use disorder". American College of Physicians, Connecticut State Chapter, Outpatient management of opioid use disorder, Southington, CT, October 2015. (Oral Presentation)
6. "Small Group Teaching". New England Region Society of General Internal Medicine Teaching Skills Retreat, Small Group Teaching, New Haven, CT, March 2016. (Oral Presentation)
7. "Why Are So Many Suboxone Patients Buying the Drug on the Street?". National Public Radio, Invited Speaker, <http://wnpr.org/post/why-are-so-many-suboxone-patients-buying-drug-street#stream/0>, Why Are So Many Suboxone Patients Buying the Drug on the Street?, New Haven, CT, September 2016. (Oral Presentation)
8. "Addicted babies and dirty addicts: Can we get in the habit of cleaning up our language?". Connecticut Opioid Response Initiative: Helping the media explain the opioid crisis and addiction to the public., Addicted babies and dirty addicts: Can we get in the habit of cleaning up our language?, New Haven, CT, June 2017. (Oral Presentation)
9. "Treatment of opioid use disorder in patients with chronic pain". Silver Hill Hospital Symposium on Opioid Epidemic, Treatment of opioid use disorder in patients with chronic pain, New Canaan, CT, October 2017. (Oral Presentation)
10. "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction". Macy Foundation. Plenary Panel Speaker for 2017 Scholar Cohort Project Proposals, Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction, New York, NY, June 2018. (Other)
11. "Approaches to substance use across the spectrum: from SBIRT to medication treatment". Approaches to substance use across the spectrum: from SBIRT to medication treatment, Approaches to substance use across the spectrum: from SBIRT to medication treatment, Hartford, CT, September 2018. (Oral Presentation)
12. "Medication Assisted Treatment Waiver Training. MAT Trainer". CT Department of Public Health Combined Scope of Pain, Medication Assisted Treatment Waiver Training. MAT Trainer, Hartford, CT, October 2018. (Other)
13. "Developing a policy agenda to ameliorate barriers and increase access to opioid agonist treatment workshop. Work group member". Drug Policy Alliance, Developing a policy agenda to ameliorate barriers and increase access to opioid agonist treatment workshop. Work group member, New York, NY, November 2018. (Other)

14. "Breaking Badness: The Internist's Role in Addiction Medicine". Greater Waterbury Research Day, Keynote Speaker, "Breaking Badness: The Internist's Role in Addiction Medicine, Waterbury, CT, June 2019. (Oral Presentation)
15. "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction". Macy Foundation. Plenary Panel Speaker for 2017 Scholar Cohort Project Updates, "Bridging the gap: Development and implementation of an inter professional, longitudinal clinical curriculum in substance use and addiction", New York, NY, June 2019. (Other)
16. "Hepatitis C in Patients with Substance Use Disorders". University of Kentucky, Hepatitis C in Patients with Substance Use Disorders, Grand Rounds Department of Psychiatry, February 2022. (Lecture)
17. "Substance Use Disorder". Yale Program in Addiction Medicine, Pain, Opioids, and Worker Wellness Training, Virtual half day training, September 2022. (Lecture)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. Effects of marijuana on pulmonary function: a systematic review. Society of General Internal Medicine (SGIM), Annual Meeting, Poster Presentation, Effects of marijuana on pulmonary function: a systematic review, Los Angeles, CA, April 2006. (Poster Presentation)
2. Risk factors associated with abuse of prescription opioids in women: results of a national survey. Society of General Internal Medicine (SGIM), Annual Meeting, Poster Presentation, Risk factors associated with abuse of prescription opioids in women: results of a national survey, Los Angeles, CA, April 2006. (Poster Presentation)
3. Factors associated with the abuse of prescription opioids in women: Results of a national survey. College on Problems of Drug Dependence (CPDD), Annual Meeting, Oral Presentation, Factors associated with the abuse of prescription opioids in women: Results of a national survey, Scottsdale, AZ, June 2006. (Oral Presentation)
4. Support and training of chief residents in management skills and conflict resolution. Association of Program Directors in Internal Medicine (APDIM) Annual Meeting, Oral Presentation, Support and training of chief residents in management skills and conflict resolution, Philadelphia, PA, September 2006. (Oral Presentation)
5. Quality of reporting of multivariable methods in the general medical literature. Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Quality of reporting of multivariable methods in the general medical literature, Toronto, ON, May 2007. (Poster Presentation)
6. Substance use in patients with sexually transmitted diseases: Results from a national survey. Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Substance use in patients with sexually transmitted diseases: Results from a national survey, Pittsburgh, PA, April 2008. (Poster Presentation)
7. Substance use in patients with sexually transmitted diseases: Results from a national survey. College on Problems of Drug Dependence (CPDD) Annual Meeting, Poster Presentation, Substance use in patients with sexually transmitted diseases: Results from a national survey, San Juan, San Juan, June 2008. (Poster Presentation)

8. Designing and implementing a multi-specialty graduate medical education curriculum on screening, brief intervention, and referral to treatment (SBIRT). Society of General Internal Medicine (SGIM) Meeting, Poster Presentation, Designing and implementing a multi-specialty graduate medical education curriculum on screening, brief intervention, and referral to treatment (SBIRT), Minneapolis, MN, May 2009. (Poster Presentation)
9. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Society of General Internal Medicine (SGIM) Meeting, Oral Presentation, Hamolsky Award Finalist., Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone, Minneapolis, MN, May 2009. (Oral Presentation)
10. HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment. College on Problems of Drug Dependence (CPDD), Oral Presentation, HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment, Scottsdale, AZ, June 2009. (Oral Presentation)
11. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. College on Problems of Drug Dependence (CPDD), Oral Presentation, Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone, Scottsdale, AZ, June 2009. (Oral Presentation)
12. Developing and Implementing a Multispecialty Graduate Medical Education Curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT). Association for Medical Education and Research in Substance Abuse, Oral Presentation, Developing and Implementing a Multi-specialty Graduate medical Education Curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT), Bethesda, MD, November 2009. (Oral Presentation)
13. Addiction update for the generalist. Society of General Internal Medicine (SGIM) Meeting, Oral Presentation, Addiction update for the generalist, Minneapolis, MN, May 2010. (Oral Presentation)
14. HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment. Society of General Internal Medicine (SGIM), Poster Presentation, HIV transmission risk behaviors and antiretroviral resistance among HIV-infected patients on opioid agonist treatment.", Minneapolis, MN, May 2010. (Poster Presentation)
15. Skills, attitudes, and training experiences regarding chronic pain management among residents. Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, Oral Presentation, Skills, attitudes, and training experiences regarding chronic pain management among residents, Arlington, VA, November 2010. (Oral Presentation)
16. Brief versus extended counseling for HIV clinic-based buprenorphine treatment of opioid dependence: Project BRIGHT. Society of General Internal Medicine (SGIM) Annual Meeting, Oral Presentation, Society of General Internal Medicine Annual Meeting, Phoenix, AZ, May 2011. (Oral Presentation)
17. Knowledge, skills and attitudes regarding identification and management of substance use among residents. Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, Poster Presentation, Knowledge, skills and attitudes regarding identification and management of substance use among residents, Arlington, VA, November 2011. (Poster Presentation)
18. Use and safety of buprenorphine in HIV-infected and uninfected opioid dependent patients. Society of General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, Use and safety

- of buprenorphine in HIV-infected and uninfected opioid dependent patients, Denver, CO, April 2013. (Poster Presentation)
19. Update in Addiction Medicine for the Generalist. Society of General Internal Medicine (SGIM) Annual Meeting, Oral Presentation, Update in Addiction Medicine for the Generalist, Phoenix, AZ, April 2013. (Oral Presentation)
 20. Actual causes of death among patients enrolled in a methadone maintenance program. American Association for the Treatment of Opioid Dependence (AATOD) Meeting, Poster Presentation, Actual causes of death among patients enrolled in a methadone maintenance program, Philadelphia, PA, November 2013. (Poster Presentation)
 21. Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program. American Society of Addiction Medicine (ASAM) Annual Meeting. Poster Presentation, Senior Author, Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program, Austin, TX, April 2015. (Poster Presentation)
 22. The Addiction Recovery Clinic: A novel primary-care based approach to teaching Addiction Medicine. Annual Meeting, Association for Medical Education and Research in Substance Abuse (AMERSA), Oral Presentation, Senior Author, The Addiction Recovery Clinic: A novel primary-care based approach to teaching Addiction Medicine, Washington, DC, November 2015. (Oral Presentation)
 23. Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Oral Presentation, Senior author, Enhanced uptake of Hepatitis C Treatment in an Opioid Treatment Program, Washington, DC, November 2015. (Oral Presentation)
 24. Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use. Society of General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use, Hollywood, FL, April 2016. (Poster Presentation)
 25. Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Poster Presentation, Outcomes of a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment for alcohol and other drug use., Washington, DC, November 2016. (Poster Presentation)
 26. Substance use disorders in hospitalized patients with cirrhosis. American Society of Addiction Medicine Annual Meeting, Poster Presentation, (Senior Author, Lead Author: Haque, L) Lead author was awarded the New Investigator of the Year Award for work on this project., Substance use disorders in hospitalized patients with cirrhosis, New Orleans, LA, April 2017. (Poster Presentation)
 27. Development of the Yale Addiction Medicine Collaborative: An Inter-professional health student addiction medicine interest group. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Poster Presentation, (Senior Author, Lead Author: Bone C), Development of the Yale Addiction Medicine Collaborative: An Inter-professional health student addiction medicine interest group, Washington, DC, November 2017. (Poster Presentation)

28. It takes a village: Implementation of substance use screening in school-based health centers. Association for Medical Education and Research and Substance Abuse (AMERSA) Annual Meeting, Oral Presentation, (Senior Author, Lead Author: Haque, L), It takes a village: Implementation of substance use screening in school based health centers, Washington, DC, November 2017. (Oral Presentation)
29. Harm reduction and opioid overdose training with naloxone for medical students in the clerkship years. Society for General Internal Medicine (SGIM) Annual Meeting, Poster Presentation, (Contributing Author, Lead Author: Oldfield, B.), Harm reduction and opioid overdose training with naloxone for medical students in the clerkship years, Denver, CO, May 2018. (Poster Presentation)
30. Contraception Use and Risk of Unintended Pregnancy among Women Enrolling in Methadone Maintenance Treatment Program. College on Problems of Drug Dependence Annual Meeting, Poster Presentation, (Contributing Author, Lead Author: Bone, C.), Contraception Use and Risk of Unintended Pregnancy among Women Enrolling in Methadone Maintenance Treatment Program, San Diego, CA, November 2018. (Poster Presentation)
31. Addiction Medicine and Psychiatry Co-visits in an Opioid Treatment Program. Association of Medical Education and Research in Substance use and Addiction (AMERSA), Annual Meeting, Poster Presentation (Contributing Author, Lead Author: Morford, K.), Addiction Medicine and Psychiatry Co-visits in an Opioid Treatment Program, San Francisco, CA, November 2018. (Poster Presentation)
32. Bridging the Gap: Development of an interprofessional workshop on taking a substance use history. Association for Multidisciplinary Education in Substance Use and Addiction (AMERSA), Bridging the Gap: Development of an interprofessional workshop on taking a substance use history, Boston, MA, November 2019. (Oral Presentation)
33. Developing a Fellowship in the New Subspecialty of Addiction Medicine. Accreditation Council of Graduate Medical Education 2020 Annual Meeting. Symposium panelist, Developing a Fellowship in the New Subspecialty of Addiction Medicine, San Diego, CA, February 2020. (Oral Presentation)
34. What Residents and Fellows Need to Know About the Intersection of Pain and Addiction. Accreditation Council on Graduate Medical Education 2020 Annual Meeting. Workshop panelist., What Residents and Fellows Need to Know About the Intersection of Pain and Addiciton, San Diego, CA, February 2020. (Oral Presentation)
35. Interprofessional Addiction Education: Implementation Strategies for Online Training. Association for Multidisciplinary Education in Substance use and Addiction Annual Meeting, Interprofessional Addiction Education: Implementation Strategies for Online Training, Contributing author. Awarded the John Nelson Chappel Best Curricula, Quality Improvement and Program Abstract Award. Conference held virtually due to COVID-19 pandemic, November 2020. (Oral Presentation)
36. Emergency Department-Initiated Buprenorphine: An Opportunity for Generalists to Collaborate with ED's to Address the Opioid Crisis. Society of General Internal Medicine, Emergency Department-Initiated Buprenorphine: An Opportunity for Generalists to Collaborate with ED's to Address the Opioid Crisis, Conference held virtually due to the COVID19 pandemic, April 2021. (Oral Presentation)
37. Building the Addiction Medicine Workforce: All Hands on Deck. American Society of Addiction Medicine Annual Meeting, Building the Addiction Medicine Workforce: All Hands on Deck, Hollywood, FL, April 2022. (Oral Presentation)

38. **Tetrault JM** . Building the Addiction Medicine Workforce: All Hands on Deck. American Society of Addiction Medicine, American Society of Addiction Medicine, Washington, DC, April 2023. (Address)
39. **Tetrault JM** , Mayyada Wazaify, Muvvala S, Minahan-Rowley R. Building Bridges Across the Glove: Developing Joint Collaborations in Interprofessional Addiction Education. International Society of Addiction Medicine, International Society of Addiction Medicine, İstanbul, İstanbul, September 2024. (Lecture)
40. **Tetrault JM** , Borelli C, Weimer MB, Butner JL. Bridging to Stability with Novel Buprenorphine Inductions. International Society of Addiction Medicine, International Society of Addiction Medicine, İstanbul, İstanbul, September 2024. (Oral Presentation)
41. **Tetrault JM** . ACAAM: Building Addiction Medicine Fellowships. American Society of Addiction Medicine, American Society of Addiction Medicine Annual Meeting, Denver, CO, April 2025. (Lecture)
42. **Tetrault JM** . The Open Access Model: An Innovative Way to Lower Opioid Treatment Program Barriers. American Society of Addiction Medicine, American Society of Addiction Medicine, Denver, CO, April 2025. (Lecture)
43. **Tetrault JM** . Key to Developing an Addiction Medicine Fellowship. American Society of Addiction Medicine, San Diego, CA, April 2026. (Oral Presentation)
44. **Tetrault JM** , Judith Tsui, Leslie Miller, Jocelyn James. Developing training programs to empower primary care and addiction medicine providers to treat Hep C: Workshop. SGIM, Society of General Internal Medicine, Washington, DC, May 2026. (Other)
45. **Tetrault JM** , Judith Tsui, Leslie Miller, David Skorvna. C Its Simple! Confidently treat Hep C using new simplified guidelines: Workshop. SGIM, Society of General Internal Medicine, Washington, DC, May 2026. (Other)

Regional

1. Hepatitis C Treatment in People with Opioid Dependence. American Academy of the Treatment of Opioid Dependence (AATOD) National Conference, Hepatitis C Treatment in People with Opioid Dependence, New York, NY, October 2009. (Oral Presentation)

Professional Service:

Peer Review Groups/Grant Study Sections

- | | |
|-------------|---|
| 2021 - 2023 | Grant Reviewer, Accreditation Council for Continuing Medical Education, Independent Grant Review Committee, Served as grant reviewer for REMS Program Companies that make and market opioids to provide commercial support to accredited continuing education for healthcare teams to promote safe prescribing and help combat the opioid crisis. Served in 2021 and 2022 |
| 2024 | Reviewer, Yale School of Medicine Women's Health Research at Yale , Member, Scientific Review Committee for grant application review |

Advisory Boards

- 2020 - 2022 Scientific Advisor, Data Safety Monitoring Board, University of Washington, Serve as Independent Safety Monitor for NIDA Funded R34 (PI Judith Tsui, MD; University of Washington) pilot study of community pharmacy model for treating people who inject drugs who are infected with Hepatitis C
- 2024 - Present Member, Data Safety and Monitoring Board: MHealth Incentivized Adherence Plus Patient Navigation Program, University of Washington

Journal Services

Editorial boards

- 2009 - 2020 Associate Editor, Alcohol, Other Drugs and Health: Current Evidence
- 2012 Guest Editor, Addiction Treatment in Medical Settings, Journal of Substance Abuse Treatment, Guest Editor for Special Issue: Addiction Treatment in Medical Settings, Journal of Substance Abuse Treatment
- 2012 Associate Editor, Medical Disorders and Complications of Addiction, for Principles of Addiction Medicine Textbook, 5th Edition
- 2019 - Present Associate Editor, Principles of Addiction Medicine Textbook 7th Edition

Reviewer

- 2005 - Present Reviewer, Reviewer for Addiction, Annals of Internal Medicine, Archives of General Psychiatry, BioMed Central: Medical Education, Clinical Medicine: Gastroenterology, Drug and Alcohol Dependence, Journal of Addiction Medicine, Journal of American Medical Association, Journal of General Internal Medicine, Journal of Managed Care, Journal of Substance Abuse Treatment, New England Journal of Medicine Substance Abuse
- 2016 Reviewer, Medical Disorders and Complications of Addiction for Principles of Addiction Medicine Textbook, 6th Edition

Professional Organizations

Addiction Medicine Fellowship Program Director's Association

- 2016 - 2018 Member, Addiction Medicine Fellowship Program Director's Association
- 2016 - 2018 Chair, Addiction Medicine Fellowship Program Director's Association

American College of Academic Addiction Medicine

- 2017 - Present Director, American College of Academic Addiction Medicine, President-elect
- 2019 - 2022 President-elect, American College of Academic Addiction Medicine, President-elect
- 2019 - Present Chair, American College of Academic Addiction Medicine, Chair, ACGME Milestones subcommittee
- 2022 - Present President, American College of Academic Addiction Medicine

American College of Physicians

- 2008 - Present Member, American College of Physicians, Connecticut Health and Public Policy Committee, Member
- 2008 - 2013 Co-Chair, American College of Physicians, Connecticut Council of Young Physicians, Co-chair
- 2008 - 2013 Member, American College of Physicians, Connecticut Governor's Council, Member
- 2009 - 2014 Chairperson, American College of Physicians, Connecticut Chapter Council of Young Physicians

American Society of Addiction Medicine

- 2012 - Present Member, American Society of Addiction Medicine
- 2013 - Present Vice Chair, American Society of Addiction Medicine, Course vice-chair, Fundamentals of Addiction Medicine Course
- 2013 - Present Member, American Society of Addiction Medicine, Continuing Medical Education Committee member
- 2013 Chair, American Society of Addiction Medicine, Planning Committee Chair, Fundamentals of Addiction Medicine Course

Association for Medical Education and Research in Substance Abuse

- 2012 - Present Member, Association for Medical Education and Research in Substance Abuse

National Institute on Drug Abuse (NIDA) Clinical Decision Support Working Group

- 2011 Expert Panel Member, National Institute on Drug Abuse (NIDA) Clinical Decision Support Working Group, Expert panel to establish Clinical Decision Support for implementation of Screening, Brief Intervention, and Referral to Treatment for Drug Use Disorders in Primary Care

National Institute on Drug Abuse (NIDA) Clinical Trials Network Subthreshold Opioid Use Disorder Intervention Workgroup

- 2018 Consultant, National Institute on Drug Abuse (NIDA) Clinical Trials Network Subthreshold Opioid Use Disorder Intervention Workgroup, Served as consultant to Clinical Trials Network panel for intervention development

Providers Clinical Support System (PCSS)

- 2010 - Present Mentor, Providers Clinical Support System (PCSS), Providers Clinical Support System: Buprenorphine Mentor
- 2012 - Present Member, Providers Clinical Support System (PCSS), Providers Clinical Support System-Opioids Member, Steering Committee

Society of General Internal Medicine

2004 - Present	Member, Society of General Internal Medicine, HIV/AIDS Task Force, Member
2004 - Present	Member, Society of General Internal Medicine, Pain Medicine Interest Group, Member
2004 - 2011	Member, Society of General Internal Medicine, Substance Abuse Interest Group, Member
2010 - Present	Reviewer, Society of General Internal Medicine, 33rd Annual Meeting, Mental Health and Substance Abuse Scientific Abstract Review Committee
2011 - 2018	Co-Chair, Society of General Internal Medicine, Alcohol, Tobacco and Other Drug Use Interest Group, Co-chair
2011 - 2014	Chairperson, Society of General Internal Medicine, Substance Abuse Interest Group
2012	Chair, Society of General Internal Medicine, 34th Annual Meeting Chair, Mental Health and Substance Abuse Workshop Review Committee
2013	Chair, Society of General Internal Medicine, 35th Annual Meeting, Chair, Mental Health and Substance Abuse Abstract Review Committee
2014	President, Society of General Internal Medicine, President elect, New England Region
2015	President, Society of General Internal Medicine, President, New England Region
2016	President, Society of General Internal Medicine, Past-president, New England Region

Yale University/VA Connecticut Healthcare System Service

2004 - Present	Committee Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Yale University Primary Care Internal Medicine Residency Program
2010 - 2016	Member, Yale University/VA Connecticut Healthcare System Service, Veterans Aging Cohort Study (VACS), Member, Liver Disease Core
2011 - 2013	Committee Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Yale University Traditional Residency Program
2013 - Present	Faculty Member, Yale University/VA Connecticut Healthcare System Service, Intern Selection Committee, Core Faculty Member HIV Training Track, Yale Primary Care Program
2016 - Present	Co-Chair, Yale University/VA Connecticut Healthcare System Service, Co-chair, Addiction Medicine curriculum committee for Yale School of Medicine
2016 - 2017	Committee Member, Yale University/VA Connecticut Healthcare System Service, Faculty Evaluation Committee, Member
2018 - Present	Member, Yale University/VA Connecticut Healthcare System Service, Member, The Committee on the Status of Women in Medicine

Yale University / Hospital System

Medical School

- 2009 - Present Member, Intern Selection Committee, Interview new applicants to Yale Primary Care Internal Medicine Residency Program
- 2021 - Present Member, YSM-YNHH Addiction Medicine/Addiction Psychiatry Services Steering Committee
- 2022 - Present Member, Yale School of Medicine-Medical Student Subcommittee of LCME Self Study, Member of the medical student subcommittee of the YSM LCME Self Study Task Force

Hospital

- 2022 - Present Member, Yale New Haven Hospital-Ambulatory treatment of OUD pathway Committee, Serve as a member of the YNHH ambulatory treatment of OUD pathway committee

Public Service / Media Presence

Media Presence

- 2016 - Present Participant, NPR, Invited guest to talk about treatment for opioid use disorder
- 2021 - Present Participant, NPR, Invited guest on CT Public Radio to discuss alcohol use disorder in women
- 2022 - Present Participant, Curbsiders Addiction Medicine Podcast, Invited speaker for podcast focusing on decreasing stigma in addiction medicine

Bibliography:

Peer-Reviewed Original Research

1. Mehra R, Moore BA, Crothers K, **Tetrault J**, Fiellin DA. The Association Between Marijuana Smoking and Lung Cancer: A Systematic Review. *JAMA Internal Medicine* 2006, 166: 1359-1367. [PMID: 16832000](#) , [DOI: 10.1001/archinte.166.13.1359](#) .
2. Sullivan LE, **Tetrault J** , Bangalore D, Fiellin DA. Training HIV Physicians to Prescribe Buprenorphine for Opioid Dependence. *Substance Use & Addiction Journal* 2006, 27: 13-18. [PMID: 17135176](#) , [DOI: 10.1300/j465v27n03_03](#) .
3. Sullivan LE, Barry D, Moore BA, Chawarski MC, **Tetrault JM** , Pantaloni MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. *Clinical Infectious Diseases* 2006, 43: s184-s190. [PMID: 17109305](#) , [DOI: 10.1086/508182](#) .
4. **Tetrault JM** , Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of Marijuana Smoking on Pulmonary Function and Respiratory Complications: A Systematic Review. *JAMA Internal Medicine* 2007, 167: 221-228. [PMID: 17296876](#) , [PMCID: PMC2720277](#) , [DOI: 10.1001/archinte.167.3.221](#) .
5. **Tetrault JM** , Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: results from a national US survey*. *Addiction* 2007, 103: 258-268. [PMID: 18042194](#) , [DOI: 10.1111/j.1360-0443.2007.02056.x](#) .

6. Becker WC, Sullivan LE, **Tetrault JM**, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: Psychiatric, medical and substance use correlates. *Drug And Alcohol Dependence* 2007, 94: 38-47. [PMID: 18063321](#) , [DOI: 10.1016/j.drugalcdep.2007.09.018](#) .
7. **Tetrault JM** , Sauler M, Wells CK, Concato J. Reporting of Multivariable Methods in the Medical Literature. *Journal Of Investigative Medicine* 2008, 56: 954-957. [PMID: 18797413](#) , [DOI: 10.2310/jim.0b013e31818914ff](#) .
8. **Tetrault J** , Sauler M, Wells C, Concato J. Reporting of Multivariable Methods in the Medical Literature. *Journal Of Investigative Medicine* 2008, 56: 954. [DOI: 10.231/jim.0b013e31818914ff](#) .
9. Barry DT, Irwin KS, Jones ES, Becker WC, **Tetrault JM** , Sullivan LE, Hansen H, O'Connor P, Schottenfeld RS, Fiellin DA. Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study. *Journal Of General Internal Medicine* 2008, 24: 218-225. [PMID: 19089500](#) , [PMCID: PMC2628993](#) , [DOI: 10.1007/s11606-008-0881-9](#) .
10. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, **Tetrault JM** , Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. *Biological Psychiatry* 2009, 66: 185-190. [PMID: 19249750](#) , [PMCID: PMC2863311](#) , [DOI: 10.1016/j.biopsych.2009.01.029](#) .
11. Gaume J, **Tetrault J** . Alcool et risques cardiovasculaires chez des hommes infectés ou non par le VIH. *Revue Médicale Suisse* 2010, 6: 2046a-2046a. [DOI: 10.53738/revmed.2010.6.268.2046a](#) .
12. Barry DT, Irwin KS, Jones ES, Becker WC, **Tetrault JM** , Sullivan LE, Hansen H, O'Connor PG, Schottenfeld RS, Fiellin DA. Opioids, Chronic Pain, and Addiction in Primary Care. *Journal Of Pain* 2010, 11: 1442-1450. [PMID: 20627817](#) , [PMCID: PMC2955997](#) , [DOI: 10.1016/j.jpain.2010.04.002](#) .
13. Gordon AJ, Kunins HV, Rastegar DA, **Tetrault JM** , Walley AY. Update in Addiction Medicine for the Generalist. *Journal Of General Internal Medicine* 2010, 26: 77-82. [PMID: 20697971](#) , [PMCID: PMC3024103](#) , [DOI: 10.1007/s11606-010-1461-3](#) .
14. **Tetrault JM** , Fiellin DA, Niccolai LM, Sullivan LE. Substance Use in Patients with Sexually Transmitted Infections: Results from a National U.S. Survey. *American Journal On Addictions* 2010, 19: 504-509. [PMID: 20958845](#) , [DOI: 10.1111/j.1521-0391.2010.00087.x](#) .
15. Sullivan LE, **Tetrault JM** , Braithwaite RS, Turner BJ, Fiellin DA. A Meta-analysis of the Efficacy of Nonphysician Brief Interventions for Unhealthy Alcohol Use: Implications for the Patient-Centered Medical Home. *American Journal On Addictions* 2011, 20: 343-356. [PMID: 21679266](#) , [DOI: 10.1111/j.1521-0391.2011.00143.x](#) .
16. **Tetrault JM** , Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV-Infected Patients Receiving Naltrexone. *Alcohol Clinical And Experimental Research* 2011, 36: 318-324. [PMID: 21797892](#) , [PMCID: PMC3221963](#) , [DOI: 10.1111/j.1530-0277.2011.01601.x](#) .
17. Holt SR, Ramos J, Harma MA, Cabrera F, Louis-Ashby C, Dinh A, **Tetrault JM** , Fiellin DA. Prevalence of Unhealthy Substance Use on Teaching and Hospitalist Medical Services: Implications for Education. *American Journal On Addictions* 2012, 21: 111-119. [PMID: 22332853](#) , [DOI: 10.1111/j.1521-0391.2011.00207.x](#) .
18. **Tetrault JM** , Green ML, Martino S, Thung SF, Degutis LC, Ryan SA, Martel S, Pantaloni MV, Bernstein SL, O'Connor P, Fiellin DA, D'Onofrio G. Developing and Implementing a Multispecialty Graduate Medical Education Curriculum on Screening, Brief Intervention, and Referral to

- Treatment (SBIRT). Substance Use & Addiction Journal 2012, 33: 168-181. [PMID: 22489589](#) , [DOI: 10.1080/08897077.2011.640220](#) .
19. McKee SA, Weinberger AH, Shi J, **Tetrault J** , Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. [PMID: 22492085](#) , [PMCID: PMC3482010](#) , [DOI: 10.1093/ntr/nts090](#) .
 20. Ryan SA, Martel S, Pantaloni M, Martino S, **Tetrault J** , Thung SF, Bernstein SL, Auinger P, Green ML, Fiellin DA, O'Connor P, D'Onofrio G. Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Alcohol and Other Drug Use among Adolescents: Evaluation of a Pediatric Residency Curriculum. Substance Use & Addiction Journal 2012, 33: 251-260. [PMID: 22738002](#) , [DOI: 10.1080/08897077.2011.640182](#) .
 21. Edelman EJ, Dinh A, Radulescu R, Lurie B, D'Onofrio G, **Tetrault JM** , Fiellin DA, Fiellin LE. Combining Rapid HIV Testing and a Brief Alcohol Intervention in Young Unhealthy Drinkers in the Emergency Department: A Pilot Study. The American Journal Of Drug And Alcohol Abuse 2012, 38: 539-543. [PMID: 22794939](#) , [PMCID: PMC3522092](#) , [DOI: 10.3109/00952990.2012.701359](#) .
 22. Fiellin LE, **Tetrault JM** , Becker WC, Fiellin DA, Hoff RA. Previous Use of Alcohol, Cigarettes, and Marijuana and Subsequent Abuse of Prescription Opioids in Young Adults. Journal Of Adolescent Health 2012, 52: 158-163. [PMID: 23332479](#) , [PMCID: PMC3552239](#) , [DOI: 10.1016/j.jadohealth.2012.06.010](#) .
 23. **Tetrault JM** , Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. [PMID: 22938914](#) , [DOI: 10.1016/j.jsat.2012.07.011](#) .
 24. Holt SR, Ramos J, Harma M, Cabrera F, Louis-Ashby C, Dinh A, Fiellin DA, **Tetrault JM** . Physician Detection of Unhealthy Substance Use on Inpatient Teaching and Hospitalist Medical Services. The American Journal Of Drug And Alcohol Abuse 2012, 39: 121-129. [PMID: 22992028](#) , [DOI: 10.3109/00952990.2012.715703](#) .
 25. Ryan S, Martel S, Pantaloni M, Martino S, **Tetrault J** , Thung S, Bernstein S, Auinger P, D'Onofrio G. Screening, brief intervention, and referral to treatment for alcohol and other drug use among adolescents: evaluation of a pediatric residency curriculum. Addiction Science & Clinical Practice 2012, 7: a98. [PMCID: PMC3480164](#) , [DOI: 10.1186/1940-0640-7-s1-a98](#) .
 26. **Tetrault JM** , Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist Treatment. Journal Of Addiction Medicine 2013, 7: 102-107. [PMID: 23388678](#) , [PMCID: PMC3618545](#) , [DOI: 10.1097/adm.0b013e31827f9bdf](#) .
 27. Rastegar DA, Kunins HV, **Tetrault JM** , Walley AY, Gordon AJ, For the US Society of General Internal Medicine's Substance Abuse Interest Group. 2012 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice 2013, 8: 6. [PMID: 23497615](#) , [PMCID: PMC3602093](#) , [DOI: 10.1186/1940-0640-8-6](#) .
 28. Udo T, Harrison EL, Shi J, **Tetrault J** , McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self-administration. American Journal On Addictions 2013, 22: 590-597. [PMID: 24131167](#) , [PMCID: PMC3934424](#) , [DOI: 10.1111/j.1521-0391.2013.12014.x](#) .

29. Becker WC, Meghani S, **Tetrault JM**, Fiellin DA. Racial/ethnic differences in report of drug testing practices at the workplace level in the U.S. American Journal On Addictions 2013, 23: 357-362. [PMID: 24112118](#) , [DOI: 10.1111/j.1521-0391.2013.12109.x](#) .
30. Gordon AJ, Bertholet N, McNeely J, Starrels JL, **Tetrault JM** , Walley AY. 2013 Update in addiction medicine for the generalist. Addiction Science & Clinical Practice 2013, 8: 18. [PMID: 24499640](#) , [PMCID: PMC3819258](#) , [DOI: 10.1186/1940-0640-8-18](#) .
31. Ebert S, **Tetrault J** . Varenicline, an optional treatment for alcohol dependence syndrome in smokers or non-smokers. Revue Médicale Suisse 2014, 10: 1893. [PMID: 25417365](#) , [DOI: 10.53738/revmed.2014.10.445.1893](#) .
32. Galbrun G, **Tetrault J** . Le [i]binge drinking[/i] chez les jeunes adultes en bonne santé augmente le risque de maladies cardio-vasculaires. Revue Médicale Suisse 2014, 10: 725-725. [DOI: 10.53738/revmed.2014.10.423.0725](#) .
33. Edelman EJ, **Tetrault JM** , Fiellin DA. Substance use in older HIV-infected patients. Current Opinion In HIV And AIDS 2014, 9: 317-324. [PMID: 24824888](#) , [PMCID: PMC4175926](#) , [DOI: 10.1097/coh.0000000000000069](#) .
34. **Tetrault JM** , McCance-Katz EF, Moody DE, Fiellin DA, Lruie BS, Dinh AT, Fiellin LE. The Impact of Recent Cocaine Use on Plasma Levels of Methadone and Buprenorphine in Patients with and Without HIV-infection. Journal Of Substance Use And Addiction Treatment 2014, 51: 70-74. [PMID: 25480096](#) , [DOI: 10.1016/j.jsat.2014.10.010](#) .
35. **Tetrault JM** , Butner JL. Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review. The Yale Journal Of Biology And Medicine 2015, 88: 227-33. [PMID: 26339205](#) , [PMCID: PMC4553642](#) .
36. Verplaetse TL, Pittman BP, Shi JM, **Tetrault JM** , Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. [PMID: 27159341](#) , [PMCID: PMC4880525](#) , [DOI: 10.1097/adm.0000000000000208](#) .
37. Becker WC, **Tetrault JM** . Medical Marijuana in Patients Prescribed Opioids A Cloud of Uncertainty. Mayo Clinic Proceedings 2016, 91: 830-832. [PMID: 27234481](#) , [DOI: 10.1016/j.mayocp.2016.04.008](#) .
38. Verplaetse TL, Pittman BP, Shi JM, **Tetrault JM** , Coppola S, McKee SA. Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clinical And Experimental Research 2016, 40: 1567-1576. [PMID: 27246567](#) , [PMCID: PMC4930423](#) , [DOI: 10.1111/acer.13110](#) .
39. **Tetrault JM** , Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. [PMID: 27431048](#) , [PMCID: PMC4976086](#) , [DOI: 10.1016/j.jsat.2016.06.002](#) .
40. Chambers D, Simpson L, Hill-Briggs F, Neta G, Vinson C, Chambers D, Beidas R, Marcus S, Aarons G, Hoagwood K, Schoenwald S, Evans A, Hurford M, Rubin R, Hadley T, Barg F, Walsh L, Adams D, Mandell D, Martin L, Mignogna J, Mott J, Hundt N, Kauth M, Kunik M, Naik A, Cully J, McGuire A, White D, Bartholomew T, McGrew J, Luther L, Rollins A, Salyers M, Cooper B, Funaiole A, Richards J, Lee A, Lapham G, Caldeiro R, Lozano P, Gildred T, Achtmeyer C, Ludman E, Addis M, Marx L,

Bradley K, VanDeinse T, Wilson A, Stacey B, Powell B, Bunger A, Cuddeback G, Barnett M, Stadnick N, Brookman-Fraze L, Lau A, Dorsey S, Pullmann M, Mitchell S, Schwartz R, Kirk A, Dusek K, Oros M, Hosler C, Gryczynski J, Barbosa C, Dunlap L, Lounsbury D, O'Grady K, Brown B, Damschroder L, Waltz T, Powell B, Ritchie M, Waltz T, Atkins D, Imel Z, Xiao B, Can D, Georgiou P, Narayanan S, Berkel C, Gallo C, Sandler I, Brown C, Wolchik S, Mauricio A, Gallo C, Brown C, Mehrotra S, Chandurkar D, Bora S, Das A, Tripathi A, Saggurti N, Raj A, Hughes E, Jacobs B, Kirkendall E, Loeb D, Trinkley K, Yang M, Sprowell A, Nease D, Lyon A, Lewis C, Boyd M, Melvin A, Nicodimos S, Liu F, Jungbluth N, Lyon A, Lewis C, Boyd M, Melvin A, Nicodimos S, Liu F, Jungbluth N, Flynn A, Landis-Lewis Z, Sales A, Baloh J, Ward M, Zhu X, Bennett I, Unutzer J, Mao J, Proctor E, Vredevoogd M, Chan Y, Williams N, Green P, Bernstein S, Rosner J, DeWitt M, **Tetrault J**, Dziura J, Hsiao A, Sussman S, O'Connor P, Toll B, Jones M, Gassaway J, Tobin J, Zatzick D, Bradbury A, Patrick-Miller L, Egleston B, Olopade O, Hall M, Daly M, Fleisher L, Grana G, Ganschow P, Fetzer D, Brandt A, Farengo-Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Chambers R, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao S, Domchek S, Hahn E, Munoz-Plaza C, Wang J, Delgadillo J, Mittman B, Gould M, Liang S, Kegler M, Cotter M, Phillips E, Hermstad A, Morton R, Beasley D, Martinez J, Riehman K, Gustafson D, Marsch L, Mares L, Quanbeck A, McTavish F, McDowell H, Brown R, Thomas C, Glass J, Isham J, Shah D, Liebschutz J, Lasser K, Watkins K, Ober A, Hunter S, Lamp K, Ewing B, Iwelunmor J, Gyamfi J, Blackstone S, Quakyi N, Plange-Rhule J, Ogedegbe G, Kumar P, Van Devanter N, Nguyen N, Nguyen L, Nguyen T, Phuong N, Shelley D, Rudge S, Langlois E, Tricco A, Ball S, Lambert-Kerzner A, Sulc C, Simmons C, Shell-Boyd J, Oestreich T, O'Connor A, Neely E, McCreight M, Labebeue A, DiFiore D, Brostow D, Ho P, Aron D, Harvey J, McHugh M, Scanlon D, Lee R, Soltero E, Parker N, McNeill L, Ledoux T, McIsaac J, MacLeod K, Ata N, Jarvis S, Kirk S, Purtle J, Dodson E, Brownson R, Mittman B, Curran G, Curran G, Pyne J, Aarons G, Ehrhart M, Torres E, Miech E, Miech E, Stevens K, I.S.R.N. Steering Council, Hamilton A, Cohen D, Padgett D, Morshed A, Patel R, Prusaczyk B, Aron D, Gupta D, Ball S, Hand R, Abram J, Wolfram T, Hastings M, Moreland-Russell S, Tabak R, Ramsey A, Baumann A, Kryzer E, Montgomery K, Lewis E, Padek M, Powell B, Brownson R, Mamaril C, Mays G, Branham K, Timsina L, Mays G, Hogg R, Fagan A, Shapiro V, Brown E, Haggerty K, Hawkins D, Oesterle S, Hawkins D, Catalano R, McKay V, Dolcini M, Hoffer L, Moin T, Li J, Duru O, Ettner S, Turk N, Chan C, Keckhafer A, Luchs R, Ho S, Mangione C, Selby P, Zawertailo L, Minian N, Balliunas D, Dragonetti R, Hussain S, Lecce J, Chinman M, Acosta J, Ebener P, Malone P, Slaughter M, Freedman D, Flocke S, Lee E, Matlack K, Trapl E, Ohri-Vachaspati P, Taggart M, Borawski E, Parrish A, Harris J, Kohn M, Hammerback K, McMillan B, Hannon P, Swindle T, Curran G, Whiteside-Mansell L, Ward W, Holt C, Santos S, Tagai E, Scheirer M, Carter R, Bowie J, Haider M, Slade J, Wang M, Masica A, Ogola G, Berryman C, Richter K, Shelton R, Jandorf L, Erwin D, Truong K, Javier J, Coffey D, Schragger S, Palinkas L, Miranda J, Johnson V, Hutcherson V, Ellis R, Kharmats A, Marshall-King S, LaPradd M, Fonseca-Becker F, Kepka D, Bodson J, Warner E, Fowler B, Shenkman E, Hogan W, Odedina F, De Leon J, Hooper M, Carrasquillo O, Reams R, Hurt M, Smith S, Szapocznik J, Nelson D, Mandal P, Teufel J. Proceedings of the 8th Annual Conference on the Science of Dissemination and Implementation. *Implementation Science* 2016, 11: 100. [PMID: 27490260](#) , [PMCID: PMC4977475](#) , [DOI: 10.1186/s13012-016-0452-0](#) .

41. Holt S, **Tetrault J** . Unhealthy Alcohol Use. *Clinics In Liver Disease* 2016, 20: 429-444. [PMID: 27373607](#) , [DOI: 10.1016/j.cld.2016.02.003](#) .

42. Donroe JH, Holt SR, **Tetrault JM** . Caring for patients with opioid use disorder in the hospital. Canadian Medical Association Journal 2016, 188: cmaj.160290. [PMID: 27647616](#) , [PMCID: PMC5135493](#) , [DOI: 10.1503/cmaj.160290](#) .
43. Blackstock OJ, Moore BA, Berkenblit GV, Calabrese SK, Cunningham CO, Fiellin DA, Patel VV, Phillips KA, **Tetrault JM** , Shah M, Edelman EJ. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. Journal Of General Internal Medicine 2016, 32: 62-70. [PMID: 27778215](#) , [PMCID: PMC5215171](#) , [DOI: 10.1007/s11606-016-3903-z](#) .
44. Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, **Tetrault JM** , Shah M, Fiellin DA, Blackstock O. Primary Care Physicians' Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. AIDS And Behavior 2016, 21: 1025-1033. [PMID: 27896552](#) , [PMCID: PMC5344709](#) , [DOI: 10.1007/s10461-016-1612-6](#) .
45. Butner JL, Gupta N, Fabian C, Henry S, Shi JM, **Tetrault JM** . Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. [PMID: 28237054](#) , [DOI: 10.1016/j.jsat.2016.12.014](#) .
46. Bernstein SL, Rosner J, DeWitt M, **Tetrault J** , Hsiao AL, Dziura J, Sussman S, O'Connor P, Toll B. Design and implementation of decision support for tobacco dependence treatment in an inpatient electronic medical record: a randomized trial. Translational Behavioral Medicine 2017, 7: 185-195. [PMID: 28194729](#) , [PMCID: PMC5526813](#) , [DOI: 10.1007/s13142-017-0470-8](#) .
47. Donroe JH, **Tetrault JM** . Substance Use, Intoxication, and Withdrawal in the Critical Care Setting. Critical Care Clinics 2017, 33: 543-558. [PMID: 28601134](#) , [DOI: 10.1016/j.ccc.2017.03.003](#) .
48. Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, **Tetrault JM** , Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. [PMID: 28440105](#) , [PMCID: PMC5823502](#) , [DOI: 10.1177/0269881117699603](#) .
49. Holt SR, Segar N, Cavallo DA, **Tetrault JM** . The Addiction Recovery Clinic. Academic Medicine 2017, 92: 680-683. [PMID: 28441678](#) , [DOI: 10.1097/acm.0000000000001480](#) .
50. Donroe JH, **Tetrault JM** . Recognizing and Caring for the Intoxicated Patient in an Outpatient Clinic. 2017, 101: 573-586. [PMID: 28372714](#) , [DOI: 10.1016/j.mcna.2016.12.012](#) .
51. **Tetrault JM** , Petrakis IL. Partnering with Psychiatry to Close the Education Gap: An Approach to the Addiction Epidemic. Journal Of General Internal Medicine 2017, 32: 1387-1389. [PMID: 28766126](#) , [PMCID: PMC5698217](#) , [DOI: 10.1007/s11606-017-4140-9](#) .
52. Donroe JH, Holt SR, O'Connor P, Sukumar N, **Tetrault JM** . Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug And Alcohol Dependence 2017, 180: 46-51. [PMID: 28866369](#) , [DOI: 10.1016/j.drugalcdep.2017.07.040](#) .
53. Deligianni M, **Tetrault J** . La réduction de la consommation de cannabis améliore les résultats fonctionnels au fil du temps. Revue Médicale Suisse 2018, 14: 2184. [PMID: 30484980](#) , [DOI: 10.53738/revmed.2018.14.629.2184](#) .
54. Holt SR, Donroe JH, Cavallo DA, **Tetrault JM** . Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug And Alcohol Dependence 2018, 186: 171-174. [PMID: 29579725](#) , [DOI: 10.1016/j.drugalcdep.2017.12.040](#) .
55. Donroe JH, **Tetrault JM** . Narrowing the treatment gap in managing opioid use disorder. Canadian Medical Association Journal 2018, 190: e236-e237. [PMID: 29507154](#) , [PMCID: PMC5837871](#) , [DOI: 10.1503/cmaj.180209](#) .

56. Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, **Tetrault JM** , Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. *Journal Of Psychopharmacology* 2018, 32: 1003-1009. [PMID: 29692206](#) , [PMCID: PMC6258014](#) , [DOI: 10.1177/0269881118767647](#) .
57. Roberts W, Shi JM, **Tetrault JM** , McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. *Journal Of Addiction Medicine* 2018, 12: 227-233. [PMID: 29438157](#) , [PMCID: PMC5970035](#) , [DOI: 10.1097/adm.0000000000000392](#) .
58. Edelman EJ, Oldfield BJ, **Tetrault JM** . Office-Based Addiction Treatment in Primary Care Approaches That Work. 2018, 102: 635-652. [PMID: 29933820](#) , [DOI: 10.1016/j.mcna.2018.02.007](#) .
59. Barakat LA, Dunne DW, **Tetrault JM** , Soares S, Chia D, Ogbuagu OE, Moriarty JP, Huot SJ, Green ML. The Changing Face of HIV Care. *Academic Medicine* 2018, 93: 1673-1678. [PMID: 29901657](#) , [DOI: 10.1097/acm.0000000000002317](#) .
60. Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, **Tetrault JM** , Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. *Journal Of Substance Use And Addiction Treatment* 2018, 97: 28-40. [PMID: 30577897](#) , [DOI: 10.1016/j.jsat.2018.11.007](#) .
61. Weimer MB, Tetrault JM, Fiellin DA. Patients with opioid use disorder deserve trained providers. *Annals of Internal Medicine*. 2019.
62. Edelman EJ, **Tetrault JM** . Unhealthy Alcohol Use in Primary Care-The Elephant in the Examination Room. *JAMA Internal Medicine* 2019, 179: 9-10. [PMID: 30422276](#) , [DOI: 10.1001/jamainternmed.2018.6125](#) .
63. Bernstein SL, Weiss J, DeWitt M, **Tetrault JM** , Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O’Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results. *Implementation Science* 2019, 14: 8. [PMID: 30670043](#) , [PMCID: PMC6343239](#) , [DOI: 10.1186/s13012-019-0856-8](#) .
64. Andrews J, Jones C, **Tetrault J** , Coontz K. Advocacy Training for Residents. *Academic Medicine* 2019, 94: 204-207. [PMID: 30334843](#) , [DOI: 10.1097/acm.0000000000002500](#) .
65. Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, **Tetrault J** , Edelman E. Integration of care for HIV and opioid use disorder. *AIDS* 2019, Publish Ahead of Print: &na;. [PMID: 30882491](#) , [PMCID: PMC6588508](#) , [DOI: 10.1097/qad.0000000000002125](#) .
66. de Laat B, Goldberg A, Shi J, **Tetrault JM** , Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O’Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. *Biological Psychiatry* 2019, 86: 864-871. [PMID: 31399255](#) , [DOI: 10.1016/j.biopsych.2019.05.021](#) .
67. Holt SR, Donroe JH, Cavallo DA, **Tetrault JM** . Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [*Drug Alcohol Depend*. 186 (2018) 171–174]. *Drug And Alcohol Dependence* 2019, 205: 107601. [PMID: 31593815](#) , [DOI: 10.1016/j.drugalcdep.2019.107601](#) .
68. Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, **Tetrault JM** , Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. *Neuropsychopharmacology* 2019, 45: 319-326. [PMID: 31590179](#) , [PMCID: PMC6901445](#) , [DOI: 10.1038/s41386-019-0536-z](#) .

69. Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham CO, Ogbuagu O, Patel VV, Phillips KA, **Tetrault JM**, Shah M, Blackstock O. Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. *Preventive Medicine Reports* 2019, 17: 101012. [PMID: 31890474](#), [PMCID: PMC6926349](#), [DOI: 10.1016/j.pmedr.2019.101012](#).
70. Dunne D, Green M, **Tetrault J**, Barakat LA. Development of a Novel Competency-Based Evaluation System for HIV Primary Care Training: the HIV Entrustable Professional Activities. *Journal Of General Internal Medicine* 2019, 35: 331-335. [PMID: 31667752](#), [PMCID: PMC6957645](#), [DOI: 10.1007/s11606-019-04956-1](#).
71. Muzyk A, Smothers ZPW, Akrobetu D, Ruiz Veve J, MacEachern M, **Tetrault JM**, Gruppen L. Substance Use Disorder Education in Medical Schools: A Scoping Review. *Academic Medicine* 2019, 94: 1825-1834. [PMID: 31663960](#), [DOI: 10.1097/acm.0000000000002883](#).
72. Kansagara D, Becker WC, Ayers C, **Tetrault JM**. Priming primary care providers to engage in evidence-based discussions about cannabis with patients. *Addiction Science & Clinical Practice* 2019, 14: 42. [PMID: 31787111](#), [PMCID: PMC6886188](#), [DOI: 10.1186/s13722-019-0171-3](#).
73. Roberts, A., Angoff, N. R., Brissette, D., Dupee, D., Fahs, D., Honan, L., Korbey, S., Roessler, E., Schwartz, M., Shabanova, V., Tetrault, J., Wu, B., Colson, E., & Encandela, J. (2020). Burnout Among Beginning First-Year Students from Three Health Professional Training Programs. *Medical Science Educator*, 30(2), 879-883. <https://doi.org/10.1007/s40670-020-00969-2>
74. Oldfield BJ, **Tetrault JM**, Wilkins KM, Edelman EJ, Capurso NA. Opioid Overdose Prevention Education for Medical Students: Adopting Harm Reduction into Mandatory Clerkship Curricula. *Substance Use & Addiction Journal* 2020, 41: 29-34. [PMID: 31211657](#), [DOI: 10.1080/08897077.2019.1621241](#).
75. Muzyk A, Smothers ZPW, Andolsek KM, Bradner M, Bratberg JP, Clark SA, Collins K, Greskovic GA, Gruppen L, MacEachern M, Ramsey SE, Ruiz Veve J, **Tetrault JM**. Interprofessional Substance Use Disorder Education in Health Professions Education Programs: A Scoping Review. *Academic Medicine* 2020, 95: 470-480. [PMID: 31651435](#), [DOI: 10.1097/acm.0000000000003053](#).
76. Roberts A, Angoff NR, Brissette D, Dupee D, Fahs D, Honan L, Korbey S, Roessler E, Schwartz M, Shabanova V, **Tetrault J**, Wu B, Colson E, Encandela J. Burnout Among Beginning First-Year Students from Three Health Professional Training Programs. *Medical Science Educator* 2020, 30: 879-883. [PMID: 34457745](#), [PMCID: PMC8368543](#), [DOI: 10.1007/s40670-020-00969-2](#).
77. **Tetrault JM**, Holt SR, Cavallo DA, O'Connor PG, Gordon MA, Corvino JK, Nich C, Carroll KM. Computerized Cognitive Behavioral Therapy for Substance Use Disorders in a Specialized Primary Care Practice: A Randomized Feasibility Trial to Address the RT Component of SBIRT. *Journal Of Addiction Medicine* 2020, 14: e303-e309. [PMID: 32371660](#), [DOI: 10.1097/adm.0000000000000663](#).
78. Haque LY, Jakab S, Deng Y, Ciarleglio MM, **Tetrault JM**. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. *Journal Of Addiction Medicine* 2020, 14: e337-e343. [PMID: 32530887](#), [PMCID: PMC9033633](#), [DOI: 10.1097/adm.0000000000000677](#).
79. Severe B, **Tetrault JM**, Madden L, Heimer R. Co-located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. *Drug And Alcohol Dependence* 2020, 213: 108116. [PMID: 32599493](#), [DOI: 10.1016/j.drugalcdep.2020.108116](#).
80. Edelman E, Oldfield B, **Tetrault J**. Office-Based Addiction Treatment in Primary Care. 2020, 9: 1-18. [DOI: 10.1016/j.ccol.2020.07.021](#).

81. Muvvala SB, Schwartz ML, Petrakis I, O'Connor P, **Tetrault JM** . Stitching A Solution to the Addiction Epidemic: A Longitudinal Addiction Curricular Thread across Four Years of Medical Training. Substance Use & Addiction Journal 2020, 41: 475-479. [PMID: 31951809](#) , [DOI: 10.1080/08897077.2019.1709606](#) .
82. Bisio C, **Tetrault J** . Association entre l'usage de cannabis et les principales anomalies congénitales. Revue Médicale Suisse 2021, 17: 1334. [PMID: 34264039](#) , [DOI: 10.53738/revmed.2021.17.745.1334](#) .
83. Smetana GW, **Tetrault JM** , Hill KP, Burns RB. Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals Of Internal Medicine 2021, 174: 237-246. [PMID: 33556279](#) , [DOI: 10.7326/m20-7945](#) .
84. Oldfield BJ, **Tetrault JM** , Berland G. Addiction Screening—The A Star Is Born Movie Series and Destigmatization of Substance Use Disorders. JAMA: The Journal Of The American Medical Association 2021, 325: 915-917. [PMID: 33687448](#) , [DOI: 10.1001/jama.2020.25256](#) .
85. Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, **Tetrault JM** , DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. [PMID: 34531767](#) , [PMCID: PMC8438169](#) , [DOI: 10.3389/fpsyt.2021.709559](#) .
86. Du CX, Shi J, **Tetrault JM** , Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice 2021, 39: 234-240. [PMID: 34893825](#) , [PMCID: PMC8947790](#) , [DOI: 10.1093/fampra/cmab166](#) .
87. Cohen SM, Weimer MB, Levander XA, Peckham AM, **Tetrault JM** , Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal Of Addiction Medicine 2021, 16: 399-406. [PMID: 34954746](#) , [DOI: 10.1097/adm.0000000000000945](#) .
88. Viera A, Grau L, Fisher J, Farnum S, **Tetrault J** , Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. Drug And Alcohol Dependence Reports 2022, 3: 100038. [PMID: 36845980](#) , [PMCID: PMC9948939](#) , [DOI: 10.1016/j.dadr.2022.100038](#) .
89. Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, **Tetrault JM** . Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. [PMID: 34483278](#) , [PMCID: PMC9033626](#) , [DOI: 10.1097/adm.0000000000000910](#) .
90. Barcelona V, Wischik DL, Marshall A, **Tetrault JM** . Integration of medication for opioid use disorder training into graduate nursing education. Nursing Forum 2022, 57: 869-873. [PMID: 35616353](#) , [DOI: 10.1111/nuf.12753](#) .
91. Morford KL, Batchelor HM, **Tetrault JM** . Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. Journal Of Addiction Medicine 2022, 16: 613-615. [PMID: 35165230](#) , [DOI: 10.1097/adm.0000000000000976](#) .
92. Morford K, **Tetrault J** , Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. [PMID: 36423462](#) , [PMCID: PMC9777057](#) , [DOI: 10.1016/j.drugalcdep.2022.109707](#) .

93. Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, **Tetrault J**, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. *JAMA Network Open* 2022, 5: e2246604. [PMID: 36515952](#) , [PMCID: PMC9856353](#) , [DOI: 10.1001/jamanetworkopen.2022.46604](#) .
94. Brooks R, Wegener M, Freeman B, Fowles C, Madden L, **Tetrault J**, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. *Health Promotion Practice* 2023, 24: 1018-1028. [PMID: 37439759](#) , [DOI: 10.1177/15248399231169791](#) .
95. Huxley-Reicher Z, Puglisi L, **Tetrault J**, Weimer M, Stellini M, Bhandary-Alexander J, Thomas K, Donroe J. Response to substance use during hospitalization: A survey study of current and ideal policies and practices. *Journal Of Hospital Medicine* 2023, 18: 829-834. [PMID: 37475186](#) , [DOI: 10.1002/jhm.13162](#) .
96. Entrup P, Brodsky L, Trimble C, Garcia S, Mohamed N, Deaner M, Martell J, Teater J, Jordan A, **Tetrault J**, Hall O. Years of life lost due to deaths of despair and COVID-19 in the United States in 2020: patterns of excess mortality by gender, race and ethnicity. *International Journal For Equity In Health* 2023, 22: 161. [PMID: 37612748](#) , [PMCID: PMC10464324](#) , [DOI: 10.1186/s12939-023-01949-9](#) .
97. Kazemitabar M, Nyhan K, Makableh N, Minahan-Rowley R, Ali M, Wazaify M, **Tetrault J**, Khoshnood K. Epidemiology of substance use and mental health disorders among forced migrants displaced from the MENAT region: A systematic review and meta-analysis protocol. *PLOS ONE* 2023, 18: e0292535. [PMID: 37797050](#) , [PMCID: PMC10553213](#) , [DOI: 10.1371/journal.pone.0292535](#) .
98. Canver B, Liptak A, Clark K, **Tetrault J**, Holt S. Preparing Physicians to Treat Addiction: Inclusion of Dedicated Addiction Training During Internal Medicine Residency. *Substance Use & Addiction Journal* 2024, 45: 408-414. [PMID: 38254274](#) , [DOI: 10.1177/29767342231224978](#) .
99. Morford K, **Tetrault J**, Fiellin D. The MATE Act: Progress for substance use education, but is checking a box enough? *Journal Of General Internal Medicine* 2024, 39: 1496-1498. [PMID: 38308156](#) , [PMCID: PMC11169132](#) , [DOI: 10.1007/s11606-024-08652-7](#) .
100. Cavallo D, Salwan J, Doernberg M, **Tetrault J**, Holt S. Shared Medical Appointment: A Novel Model for Incorporating Group Visits Into Residency Training for Substance Use Disorders. *Substance Use & Addiction Journal* 2024, 45: 466-472. [PMID: 38494709](#) , [DOI: 10.1177/29767342241233363](#) .
101. Abdulfattah S, Ahmad A, Kitaneh R, Alsharaydeh T, Almudallal F, Alzoubi R, Abbadi R, Haddad T, Wazaify M, Alkayed Z, Mustafa R, **Tetrault J** . Nonmedical Use of Stimulants Among Students in Jordan: A Nationwide Study. *Journal Of Addiction Medicine* 2024, 18: 443-450. [PMID: 38587298](#) , [DOI: 10.1097/adm.0000000000001308](#) .
102. Mahoney B, Morford K, Biegacki E, **Tetrault J** . Hepatitis C virus and integrated care for substance use disorders. *Clinical Liver Disease* 2024, 23: e0241. [PMID: 38952692](#) , [PMCID: PMC11216679](#) , [DOI: 10.1097/cld.0000000000000241](#) .
103. Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, **Tetrault J** , Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. *Drug And Alcohol Dependence* 2024, 260: 110649. [DOI: 10.1016/j.drugalcdep.2023.110649](#) .

104. Samberg D, Spinella S, Rothenberger S, **Tetrault J**, Childers J. Impact of a Web-Based Curriculum on Internal Medicine Resident Use of Stigmatizing Language for Substance Use Disorder. *Substance Use & Addiction Journal* 2024, 46: 313-319. [PMID: 39690470](#) , [DOI: 10.1177/29767342241298057](#) .
105. Hall O, Trimble C, Garcia S, Grayson S, Joseph L, Entrup P, Jegede O, Martel J, **Tetrault J** , Mathis M, Jordan A. Who feels safe calling 911: are prior experiences of anti-Black racial discrimination associated with hesitancy seeking emergency medical services in the event of accidental drug overdose? – a study protocol. *Annals Of Medicine* 2024, 57: 2439540. [PMID: 39697058](#) , [PMCID: PMC11660366](#) , [DOI: 10.1080/07853890.2024.2439540](#) .
106. Wazaify M, Al-Khateeb Y, Khoshnood K, Muvvala S, Minahan-Rowley R, Abu-Dahab R, **Tetrault J** . Novel Elective Course on Substance Use for Pharmacy Students in Jordan. *American Journal Of Pharmaceutical Education* 2025, 89: 101399. [PMID: 40158728](#) , [DOI: 10.1016/j.ajpe.2025.101399](#) .
107. Muvvala S, Minahan-Rowley R, Al-Khateeb Y, Abu-Dahab R, Khoshnood K, Wazaify M, **Tetrault J** . Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program. *Substance Use & Addiction Journal* 2025, 46: 1013-1018. [PMID: 40913374](#) , [DOI: 10.1177/29767342251331389](#) .
108. Cohen S, Straus E, Fiellin D, Pomeranz J, Suzuki J, **Tetrault J** , Weimer M, Edelman E, Joudrey P. Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services. *JAMA Network Open* 2025, 8: e2526077. [PMID: 40773194](#) , [PMCID: PMC12332638](#) , [DOI: 10.1001/jamanetworkopen.2025.26077](#) .
109. Cohen S, **Tetrault J** , Hill G. Effect of Acupuncture for Methadone Reduction. *Annals Of Internal Medicine* 2025, 178: 1212. [PMID: 40825221](#) , [DOI: 10.7326/annals-25-01517](#) .
110. Nkemjika S, Hall O, **Tetrault J** , Jordan A. Sociodemographic Determinants of Telehealth Visits: A Comparison of Mental Health and Substance Use Disorders with Other Services. *Epidemiologia* 2025, 6: 54. [PMID: 40981085](#) , [PMCID: PMC12452398](#) , [DOI: 10.3390/epidemiologia6030054](#) .
111. Morford K, **Tetrault J** , O'Connor P. Alcohol and Cancer Risk. *JAMA: The Journal Of The American Medical Association* 2025, 334: 908-909. [PMID: 40768234](#) , [DOI: 10.1001/jama.2025.11229](#) .
112. Morford K, **Tetrault J** , O'Connor P. Alcohol and Cancer—Reply. *JAMA: The Journal Of The American Medical Association* 2026, 335: 94-94. [PMID: 41324920](#) , [DOI: 10.1001/jama.2025.19212](#) .
113. Heiman E, Manhapra AJ, Tetrault JM. Medical Comorbidities. In 3rd Edition of Office Based Buprenorphine Treatment for Opioid Use Disorder. American Psychiatric Association. Eds John Renner and Joji Suzuki

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Tetrault JM, Crothers K. Clinical update: What are the pulmonary effects of smoking marijuana? *The Journal of Respiratory Diseases*. 2007, 28(6):253-254
2. Tetrault JM, Fiellin DA, Sullivan LE. Substance Use and HIV: Treatment Challenges. *The AIDS Reader* 2019, Vol. No. August 3, 2010

Peer-Reviewed Educational Materials

1. Tetrault JM, O'Connor PG. Unhealthy alcohol use, including alcohol use disorder: Epidemiology, pathogenesis, clinical manifestations, course assessment, and diagnosis. UpToDate Topic. December, 2014. Updated Sept 13, 2018.

2. International AIDS Society Cases on the Web Activity. October 21, 2015, Updated November 1, 2016
3. Holt SR, Tetrault JM. Ambulatory management of alcohol withdrawal syndrome. UpToDate topic. 2016. Updated Nov 30, 2017
4. Tetrault JM and Edelman EJ. Considerations in the treatment of opioid use disorder in patients with HIV infection and HIV/HCV coinfection. International Antiviral Society (IAS)-USA. May, 21, 2019. <https://www.iasusa.org/courses/cow94/>

Peer-Reviewed Case Reports and Technical Notes

1. Kansagara DL, **Tetrault J**, Hamill C, Moore C, Olson B. Fatal Factitious Cushing's Syndrome and Invasive Aspergillosis: Case Report and Review of Literature. Endocrine Practice 2006, 12: 651-655. [PMID: 17229661](#) , [DOI: 10.4158/ep.12.6.651](#) .

Books

1. Tetrault JM, Sullivan LE, Fiellin DA. Medical Management in Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
2. Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
3. Editors: Shannon C. Miller MD, DFASAM, DLFAPA, Richard N. Rosenthal MD, MA, DLFAPA, DFAAAP, F, Sharon Levy MD, MPH, FASAM, FAAP, Andrew J. Saxon MD, FASAM, Jeanette M. Tetrault MD, FACP, FASAM, Sarah E. Wakeman MD, FASAM Publisher: Wolters Kluver

Chapters

1. Tetrault JM, O'Connor PG. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Fourth Edition. Lippincott, Williams & Wilkins, Inc. Philadelphia, PA 2009, Pp 589-603.
2. Tetrault JM, Sullivan LE, Fiellin DA, Medical Management in Handbook of Office Based Buprenorphine for Opioid Dependence. 2011. Renner JA, Levounis P, eds. American Psychiatric Publishing. Pp 239-267.
3. Tetrault JM, O'Connor. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Fifth Edition. Wolters Kluwer. Philadelphia, PA. 2014. Pp 668-685.
4. Tetrault JM, O'Connor PG. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine, Sixth Edition. Wolters Kluwer. Philadelphia, PA. 2018. Pp 741-756.
5. Morford K and Tetrault JM. Opioid Intoxication and Withdrawal. In Principles of Addiction Medicine: The Essentials, Third Edition. Lippincott, Williams & Wilkins, Inc. Philadelphia, PA. 2019.
6. Morford, KL, Falker CG, Tetrault, JM. in Treating Opioid Use Disorder in General Medical Settings. Editor, Wakeman, SE.
7. Robinson, D and Tetrault JM. 2021. "Treatment of Opioid Use Disorder" in Pocket Addiction Medicine. Editors: Wakeman, SE, Lee JD, Alvanzo A. Published by Wolters Kluwer.
8. Morford K, Falker C, **Tetrault J** . Training Medical Students, Residents, and Fellows in Opioid Use Disorder Treatment. 2021, 161-171. [DOI: 10.1007/978-3-030-80818-1_11](#) .

9. Shi J, Slocum B, **Tetrault J**, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. [DOI: 10.1016/b978-0-323-79016-1.00008-8](https://doi.org/10.1016/b978-0-323-79016-1.00008-8) .
10. Chan C, **Tetrault J**, Holt S. Leading a Substance Use Disorder Clinic. 2023, 255-274. [DOI: 10.1007/978-3-031-40273-9_17](https://doi.org/10.1007/978-3-031-40273-9_17) .

Commentaries, Editorials and Letters

1. **Tetrault JM**, O'Connor PG. Substance Abuse and Withdrawal in the Critical Care Setting. Critical Care Clinics 2008, 24: 767-788. [PMID: 18929942](https://pubmed.ncbi.nlm.nih.gov/18929942/) , [DOI: 10.1016/j.ccc.2008.05.005](https://doi.org/10.1016/j.ccc.2008.05.005) .
2. **Tetrault JM**, Fiellin DA. Adding buprenorphine implants to counselling reduces opioid use over 6 months in opioid-dependent adults. BMJ Mental Health 2011, 14: 30. [PMID: 21266627](https://pubmed.ncbi.nlm.nih.gov/21266627/) , [DOI: 10.1136/ebmh.14.1.30](https://doi.org/10.1136/ebmh.14.1.30) .
3. **Tetrault JM**, Fiellin DA. Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals. Drugs 2012, 72: 217-228. [PMID: 22235870](https://pubmed.ncbi.nlm.nih.gov/22235870/) , [PMCID: PMC3701303](https://pubmed.ncbi.nlm.nih.gov/PMC3701303/) , [DOI: 10.2165/11597520-000000000-00000](https://doi.org/10.2165/11597520-000000000-00000) .
4. Walley AY, **Tetrault JM**, Friedmann PD. Integration of substance use treatment and medical care: A special issue of JSAT. Journal Of Substance Use And Addiction Treatment 2012, 43: 377-381. [PMID: 23079197](https://pubmed.ncbi.nlm.nih.gov/23079197/) , [DOI: 10.1016/j.jsat.2012.09.002](https://doi.org/10.1016/j.jsat.2012.09.002) .
5. **Tetrault JM**, Fiellin DA. More Beds or More Chairs? Using a Science-Based Approach to Address the Opioid Epidemic. Annals Of Internal Medicine 2017, 168: 73-74. [PMID: 29159399](https://pubmed.ncbi.nlm.nih.gov/29159399/) , [DOI: 10.7326/m17-2854](https://doi.org/10.7326/m17-2854) .
6. Weimer MB, Tetrault JM, Allen JC. We must invest in addiction treatment providers. New Haven Register. Op-Ed. March 25, 2019
7. Morford, KM, Tetrault JM. Building the addiction medicine workforce to address the opioid epidemic: Critical steps for medical education. Connecticut Medicine. 2019. 83 (5): 211-216.
8. Weimer MB, **Tetrault JM**, Fiellin DA. Patients With Opioid Use Disorder Deserve Trained Providers. Annals Of Internal Medicine 2019, 171: 931-932. [PMID: 31766053](https://pubmed.ncbi.nlm.nih.gov/31766053/) , [DOI: 10.7326/m19-2303](https://doi.org/10.7326/m19-2303) .
9. Weimer MB, **Tetrault JM**, Fiellin DA. Patients With Opioid Use Disorder Deserve Trained Providers. Annals Of Internal Medicine 2020, 172: 774-775. [PMID: 32479150](https://pubmed.ncbi.nlm.nih.gov/32479150/) , [DOI: 10.7326/l20-0084](https://doi.org/10.7326/l20-0084) .
10. Chan CA, **Tetrault JM**, Fiellin DA, Weimer MB. SOAPs and SUDs: Patients With Substance Use Disorders and What Clinicians Should Know About the Cures Act. Journal Of Addiction Medicine 2021, 16: 141-142. [PMID: 34049315](https://pubmed.ncbi.nlm.nih.gov/34049315/) , [DOI: 10.1097/adm.0000000000000879](https://doi.org/10.1097/adm.0000000000000879) .
11. Biegacki ET, **Tetrault JM**, Fiellin DA. Commentary Article: Strategic Planning for Addiction Programs within Academic Medical Centers: Examples from the Yale Program in Addiction Medicine. Substance Use & Addiction Journal 2022, 43: 1215-1220. [PMID: 35657646](https://pubmed.ncbi.nlm.nih.gov/35657646/) , [DOI: 10.1080/08897077.2022.2074606](https://doi.org/10.1080/08897077.2022.2074606) .
12. Miller S, Levy S, Saxon A, **Tetrault J**, Rosenthal R, Wakeman S, Vocci F. Revisiting Preaddiction. Journal Of Addiction Medicine 2024, 18: 486-487. [PMID: 39356619](https://pubmed.ncbi.nlm.nih.gov/39356619/) , [DOI: 10.1097/adm.0000000000001357](https://doi.org/10.1097/adm.0000000000001357) .